We presented a retrospective study showing that from patients not 
receiveing alllo-HCT at CR-1, at 10 years 16.6% of patients aged <60 
years and 2.4% of those aged ≥60 years were alive and disease-free. This 
disease-free AML group consisted predominantly of patients with 
core-binding factor AML with t(8;21)(q22;q22) or 
inv(16)(p13q22)/t(16;16)(p13;q22) and those with a normal karyotype.

Presenter: Prof. Spyridonidis
Particiapants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Bountouris